These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 21262850)
1. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850 [TBL] [Abstract][Full Text] [Related]
2. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. Cowan A; Raffa RB; Tallarida CS; Tallarida RJ; Christoph T; Schröder W; Tzschentke TM Eur J Pain; 2014 Sep; 18(8):1148-56. PubMed ID: 24574066 [TBL] [Abstract][Full Text] [Related]
3. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444 [TBL] [Abstract][Full Text] [Related]
5. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain. Schiene K; De Vry J; Tzschentke TM J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956 [TBL] [Abstract][Full Text] [Related]
6. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Bee LA; Bannister K; Rahman W; Dickenson AH Pain; 2011 Jan; 152(1):131-139. PubMed ID: 21187272 [TBL] [Abstract][Full Text] [Related]
7. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022 [TBL] [Abstract][Full Text] [Related]
8. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview]. Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822 [TBL] [Abstract][Full Text] [Related]
9. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy. Gonçalves L; Friend LV; Dickenson AH Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174 [TBL] [Abstract][Full Text] [Related]
10. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. Tzschentke TM; Christoph T; Kögel BY CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192 [TBL] [Abstract][Full Text] [Related]
11. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice. Kögel B; De Vry J; Tzschentke TM; Christoph T Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580 [TBL] [Abstract][Full Text] [Related]
12. Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'. Raffa RB; Elling C; Tzschentke TM Adv Ther; 2018 Oct; 35(10):1471-1484. PubMed ID: 30206823 [TBL] [Abstract][Full Text] [Related]
13. Effect of tapentadol on neurons in the locus coeruleus. Torres-Sanchez S; Alba-Delgado C; Llorca-Torralba M; Mico JA; Berrocoso E Neuropharmacology; 2013 Sep; 72():250-8. PubMed ID: 23664814 [TBL] [Abstract][Full Text] [Related]
14. Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach. Falk S; Patel R; Heegaard A; Mercadante S; Dickenson AH Eur J Pain; 2015 Feb; 19(2):152-8. PubMed ID: 24917026 [TBL] [Abstract][Full Text] [Related]
15. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain. Mao XF; Ahsan MZ; Apryani E; Tang XQ; Zhao MJ; Li XY; Wang YX Eur J Pharmacol; 2020 Jun; 876():173062. PubMed ID: 32173379 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo characterization of tapentadol metabolites. Terlinden R; Kogel BY; Englberger W; Tzschentke TM Methods Find Exp Clin Pharmacol; 2010; 32(1):31-8. PubMed ID: 20383344 [TBL] [Abstract][Full Text] [Related]
18. μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons. Sadeghi M; Tzschentke TM; Christie MJ Br J Pharmacol; 2015 Jan; 172(2):460-8. PubMed ID: 24372103 [TBL] [Abstract][Full Text] [Related]
19. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model. Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165 [TBL] [Abstract][Full Text] [Related]
20. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence. Ahsan MZ; Zhao MJ; Shoaib RM; Zhang Y; Wang YX Life Sci; 2021 Nov; 285():119996. PubMed ID: 34597607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]